The FDA approved Stoboclo and Osenvelt, denosumab biosimilars that could offer more affordable treatment options for ...

Stoboclo, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Osenvelt, a ...

Should you take a calcium supplement? And if so, how much? Here's what to know about calcium's benefits and some warnings.

Patients with postmenopausal osteoporosis who received Ospomyv experienced several common adverse events (AEs), including back pain, extremity pain, hypercholesterolemia, musculoskeletal pain ...

Since you can’t see your bones aging, you should be proactive about preventing osteoporosis. Atrium Health’s Fracture ...

There is also an increased risk of falls and fractures. Osteoporosis, which disproportionately affects postmenopausal ...

Ankylosing spondylitis (AS) can increase your risk of developing osteoporosis. Some lifestyle changes may help delay or prevent its development. AS is a chronic, inflammatory condition that causes ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.

Women’s bone health often takes a backseat as they juggle work, home, and caregiving responsibilities, leading to neglected mobility, joint strength, and overall musculoskeletal well-being.

STOBOCLO ® (denosumab-bmwo) and OSENVELT ® (denosumab-bmwo) are approved by FDA for all indications of reference products ...

“We have a longstanding and productive partnership with Amneal, and we are pleased to be advancing these two important products to the U.S. biosimilar market. We remain focused on our globalization ...

Prolia®: In patients with postmenopausal osteoporosis, the most frequently reported adverse reactions included back musculoskeletal and extremity pain; hypercholesterolemia; and cystitis.